Statins Soon After Diabetes Diagnosis May Cut Dementia Risk
A Danish study of over 132,000 people found that starting statins within a year of a type 2 diabetes diagnosis was associated with a 15% lower relative risk of developing dementia over 10 years. The findings were presented at ESC Congress 2026 and published in The Lancet Regional Health – Europe. Researchers suggest that managing cholesterol early may help reduce dementia risk.
The investigation leveraged Danish national health registries, tracking over 132,000 adults newly diagnosed with type 2 diabetes between 2006 and 2019. A specialized statistical approach, designed to mimic a randomized controlled trial, was used to compare dementia outcomes among those who initiated statins at different intervals post-diagnosis.
Over a median follow-up of roughly seven years, dementia occurred in 2.7% of the cohort. While early statin initiation (within one year) showed a 15% relative risk reduction, starting therapy between one and five years still yielded a 10% reduction, with consistent findings across sexes. The authors highlight that statins are frequently underutilized in diabetic patients despite established cardiovascular benefits.
This observational evidence could influence clinical practice by encouraging earlier cholesterol management in newly diagnosed diabetic patients, potentially reducing the future societal burden of dementia. If replicated, it may prompt physicians to view statin prescriptions not only as cardiovascular protection but also as a possible neurological safeguard. Given the aging population and lack of dementia cures, even modest relative risk reductions could translate into substantial public health benefits, though causality remains unproven.